Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Shares in Alnylam were up almost 56% at one point yesterday, while rival Ionis saw its shares slump 9%. Shares in The Medicines Company were also up 5.7% thanks to an RNAi licensing deal with Alnylam.

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic ...

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, Cardiovascular Disease, and Neuroscience, each representing a blockbuster opportunity ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday ...